Compare PAX & DMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PAX | DMRA |
|---|---|---|
| Founded | 1988 | 2011 |
| Country | Cayman Islands | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.5B |
| IPO Year | 2020 | 2020 |
| Metric | PAX | DMRA |
|---|---|---|
| Price | $11.25 | $28.14 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 2 |
| Target Price | $18.00 | ★ $43.00 |
| AVG Volume (30 Days) | ★ 1.2M | 316.3K |
| Earning Date | 05-05-2026 | 05-11-2026 |
| Dividend Yield | ★ 4.81% | N/A |
| EPS Growth | N/A | ★ 121.48 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $12.99 | N/A |
| Revenue Next Year | $16.52 | N/A |
| P/E Ratio | $25.65 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.55 | $16.50 |
| 52 Week High | $17.80 | $34.89 |
| Indicator | PAX | DMRA |
|---|---|---|
| Relative Strength Index (RSI) | 47.81 | 41.90 |
| Support Level | $11.04 | $28.16 |
| Resistance Level | $11.58 | $28.66 |
| Average True Range (ATR) | 0.32 | 1.58 |
| MACD | -0.02 | -0.42 |
| Stochastic Oscillator | 39.39 | 25.37 |
Patria Investments Ltd is an alternative asset management firm specializing in resilient sectors across select regions. It seeks to provide world-wide and Latin American investors with attractive investment products that allows portfolio diversification and consistent returns. The group promotes inclusive and sustainable development in the Asset Classes: Private Equity, Private Equity Solutions, Credit, Real Estate, Infrastructure, and Public Equities Main sectors: Agribusiness, Power & Energy, Healthcare, Logistics & Transportations, Food & Beverage and Digital & Tech Services Investment Regions.
Damora Therapeutics Inc is a biotechnology company that aims to fundamentally redefine care for people with hematologic disorders. The group is advancing a new generation of biologics to treat mutant calreticulin-driven myeloproliferative neoplasms, including essential thrombocythemia and myelofibrosis, where there is cruicial medical need for disease-modifying treatments. Its goal is to rapidly bring forward optimized therapies with broad mutation coverage and exceptional convenience to dramatically improve patient outcomes. The group's pipeline products are DMR-001, DMR-002, DMR-003, and GB3226.